Evaluation of serum soluble triggering receptor expressed on myeloid cells-1 in polycystic ovary syndrome
TL;DR
Soluble triggering receptor expressed on myeloid cells-1 may serve as an indicator of the chronic inflammatory process in polycystic ovary syndrome and could be a complementary marker rather than a diagnostic marker for polycystic ovary syndrome.
Abstract
SUMMARY
Objective
This study aims to investigate the clinical significance of serum soluble triggering receptor expressed on myeloid cells-1 levels in patients with polycystic ovary syndrome.
Methods
This case-control study included 40 women with polycystic ovary syndrome and 40 healthy control women. Serum soluble triggering receptor expressed on myeloid cells-1 and high-sensitive C-reactive protein levels were measured via commercially available enzyme-linked immunosorbent assay, according to the manufacturer's instructions.
Results
Soluble triggering receptor expressed on myeloid cells-1 levels were statistically significantly higher in women with polycystic ovary syndrome than controls (p<0.001). In the logistic regression analysis, an increase in serum soluble triggering receptor expressed on myeloid cells-1 level demonstrated a significant association with polycystic ovary syndrome diagnosis (p=0.011). In the receiver operating characteristic curve analysis, the area under the curve (AUC) for soluble triggering receptor expressed on myeloid cells-1 was found to be 0.800 (p<0.001). Setting the cut-off value at 45.22 pg/mL, soluble triggering receptor expressed on myeloid cells-1 demonstrated a sensitivity of 87.5% and a specificity of 65.0%. In the logistic regression analysis that incorporated homeostatic model assessment for insulin resistance, anti-müllerian hormone, and soluble triggering receptor expressed on myeloid cells-1, a 1 pg/mL rise in soluble triggering receptor expressed on myeloid cells-1 was associated with a 1.07-fold increase in the odds of polycystic ovary syndrome, a 3.10-fold increase in the odds due to a 1-point rise in homeostatic model assessment for insulin resistance, and a 3.24-fold increase in the odds for every 1 ng/mL rise in anti-müllerian hormone. The model incorporating anti-müllerian hormone, homeostatic model assessment for insulin resistance, and soluble triggering receptor expressed on myeloid cells-1 predicted polycystic ovary syndrome with 83.8% accuracy, 90.0% specificity, and 77.5% sensitivity.
Conclusion
Soluble triggering receptor expressed on myeloid cells-1 may serve as an indicator of the chronic inflammatory process in polycystic ovary syndrome and could be a complementary marker rather than a diagnostic marker for polycystic ovary syndrome.
